CRMD CorMedix Inc.

BUSINESS SUMMARY

CorMedix sells DefenCath, an FDA-approved catheter lock solution designed to reduce catheter-related bloodstream infections (CRBSIs) in patients receiving hemodialysis through a central venous catheter.

DefenCath is a combination of taurolidine (an antimicrobial) and heparin (an anticoagulant). The solution is instilled into the catheter lumen between dialysis sessions, where it both prevents bacterial growth and maintains catheter patency. FDA approval came in November 2023 for the dialysis indication; commercial launch began Q1 2024.

Revenue is per-vial pricing to dialysis providers (DaVita, Fresenius, US Renal Care, smaller chains), reimbursed via a CMS pass-through code that provides separate payment outside the bundled dialysis rate.

MARKET OPPORTUNITY

The US dialysis market is highly concentrated and structurally dependent on infection-prevention economics:

• ~600,000 US dialysis patients, with the catheter sub-population representing roughly 20-25%
• Each CRBSI episode costs the healthcare system $30,000-$70,000 and meaningfully harms patient outcomes
• CMS pass-through payment provides reimbursement clarity for dialysis providers, removing the bundled-rate disincentive

Where CorMedix is exposed:

• Big-three dialysis providers (DaVita, Fresenius, US Renal Care) are the primary customer concentration
• Hospital-based dialysis (smaller percentage but higher per-patient revenue when used)
• Future indications — TPN (total parenteral nutrition) and pediatric oncology are obvious extension targets but not yet on label

Macro context: the revenue growth of 617% YoY is the post-launch S-curve from near-zero. This pattern will normalize over 6-12 months as the major dialysis providers complete their adoption.

REVENUE QUALITY

The economics are exceptional for a small-cap pharma:

• Gross margin 87.7% — high; reflects the proprietary formulation and per-vial pricing
• Operating margin near 0% — just turned profitable on a TTM basis after the launch ramp absorbed sales-force expense
• Revenue $312M TTM — meaningful absolute base, large enough that quarterly revenue moves carry information rather than being noise
• P/S ~2 — modest for a recently-FDA-approved drug with this growth profile; cheapness reflects revenue-concentration risk being priced

What hides in the data: revenue concentration in DaVita and Fresenius. The two account for the majority of US dialysis treatments and therefore the majority of DefenCath demand. A renegotiation with either is a material event.

COMPETITIVE ADVANTAGE

The defensible asset is the FDA approval plus the CMS pass-through reimbursement code:

• First-in-indication FDA approval — competitor entry requires de-novo clinical trials and approval, a 5+ year project
• CMS transitional pass-through code is the reimbursement enabler — without it, the bundled-rate would disincentivize provider use
• Patent and exclusivity protection through ~2030

What it is not: a moat against off-label alternatives. Some clinicians use saline-and-heparin lock or alternative antimicrobial-locks off-label. The economic case for DefenCath has to keep beating the alternatives' lower acquisition cost via reduced infection rate.

GROWTH THESIS

Three things have to work:

1. Big-three adoption depth grows. Each major chain has rolled out DefenCath unevenly across their facility footprint; deepening per-facility utilization is the cleanest growth lever.
2. CMS pass-through renews favorably. The pass-through is time-limited; renewal terms set the multi-year reimbursement floor.
3. Pipeline expansion (TPN, pediatric oncology) provides the second-act for revenue diversification beyond dialysis.

KEY RISKS

Three specific risks:

1. DaVita / Fresenius concentration. The two account for the majority of US dialysis. A renegotiation, formulary change, or strategic decision by either could materially affect quarterly revenue.

2. CMS pass-through expiry or compression. The transitional pass-through is finite-duration. Unfavorable renewal would compress per-vial economics regardless of clinical efficacy.

3. Off-label competition. If clinicians revert to saline-heparin lock or alternative antimicrobial-locks at scale, DefenCath utilization compresses without any clinical-evidence change.

VERDICT

The 87.7/100 score is genuinely earned — meaningful absolute revenue, FDA-approved product, just-turned-profitable. The revenue base of $312M is large enough that this is no longer a launch-story but a commercialized-product story; the multiple is correspondingly more defensible than for the typical sub-$100M-revenue first-launch peer.

For investors who want exposure to commercialized FDA-approved pharma at small-cap scale and can underwrite dialysis-customer concentration, CRMD is one of the cleaner names available. For investors needing diversified revenue or counter-cyclical exposure, the customer-concentration is disqualifying.

The single metric to watch next is DefenCath utilization rate at DaVita and Fresenius facilities, disclosed in periodic earnings. Continued depth-of-penetration means the launch is intact; a plateau signals revenue is approaching the per-customer ceiling.